

**The announcement of Inter Cyto Nano Science and Dr. Jun Fujita, professor of the Kyoto University,
agreed on a patent licensing of production yield improvement of recombinant protein**

Inter Cyto Nano Science Co., Ltd. and Dr. Jun Fujita, a professor of the Kyoto University, today announced that an agreement on a patent licensing which is related to production yield improvement of recombinant protein. We have just entered into an agreement, granting an exclusive patent (being applied under Dr. Fujita's proprietary) licensing right of "The response element in mammalian cells to mild hypothermia", which gives much effect to the improvement of production yield of the recombinant protein, for which sugar chain is indispensable.

Dr. Fujita invented that an element, which promotes the expression of gene under hypothermia in industrial use of bacteria such as E-coli. does exist also in mammalian cells. The improvement of production yield of recombinant protein such as monoclonal antibodies and erythropoietin has been a pharmaceutical researchers' long time assignment. And, recently, though the technology is being improved by gene technology and the development of cell culture, the combination with the conventional technologies reaches its limit.

The invention of Dr. Fujita improves the production yield of conventional technologies, and in particular, when milligram order dosage per patient of the recombinant protein such as monoclonal antibodies is necessary, it is anticipated that the manufacturing cost will be decreased drastically.

Inter Cyto Nano Science Co., Ltd. will drive sub-licensing of the non-exclusive patent right to the manufacturers of the recombinant protein or to those who are planning, and the company will embark on contribution to the world's pharmaceutical industry by materializing a positive manufacturing cost down of recombinant proteins.

Dr. Jun Fujita

Dr. Fujita is a professor of the Department of Clinical Molecular Biology, Graduate School of Medicine, Kyoto University and also one of the technical advisors of Inter Cyto Nano Science Co., Ltd. He has been studying of hepatocarcinogenesis and the cold shock response, and the identification of the liver oncogene, Gankyrin, is noteworthy, because Gankyrin could be a good target for developing therapeutic and preventive strategies against human hepatocellular carcinomas. .

Also, he is known as a founder of the inter-net site "IdenNet", and at present, serves as the president of the Japanese Society for Genetics Counseling.

Inter Cyto Nano Science Co., Ltd.

Inter Cyto Nano Science has a unique business model of mediating between academies and pharmaceutical industries. At various development stages, the company introduces small molecule design for new medicinal products, based on the information obtained through analysis of molecule function and of protein structure, making good use of the latest biotechnology and nanotechnology originated from the ten laboratories of 5 universities, Osaka, Kyoto, Osaka Prefecture, Kumamoto and Kagoshima.

Contact Person

MASATO HOSODA

e-mail : masato-hosoda@intercyto.jp